#1 Clinical Trials Search in Europe

Pamidronate Disodium

Pamidronate Disodium, a bisphosphonate medication, is being studied in various clinical trials to assess its effectiveness in treating different medical conditions. These trials aim to evaluate the drug’s potential in managing bone-related disorders, cancer-associated complications, and other health issues. This article provides an overview of the ongoing research and potential applications of Pamidronate Disodium in clinical settings.

Table of Contents

What is Pamidronate Disodium?

Pamidronate Disodium is a medication that belongs to a class of drugs called bisphosphonates. It is also known by several other names, including Aminomux, APD, Aredia, and GCP-23339A[4]. This drug is primarily used to treat conditions affecting bone health and to manage certain types of cancer that impact the bones.

Conditions Treated with Pamidronate

Pamidronate is used to treat various conditions related to bone health and certain cancers. Some of the main conditions it’s used for include:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[6]
  • Bone Metastases: When cancer spreads to the bones, particularly in breast cancer patients[7]
  • Avascular Necrosis of the Femoral Head: A condition where bone tissue dies due to lack of blood supply[1]
  • SAPHO Syndrome: A rare condition affecting the skin, bones, and joints[2]
  • Bone Loss after Organ Transplantation: Particularly after liver and kidney transplants[3][8]
  • Chronic Low Back Pain: In some cases, pamidronate is being studied for its potential in managing chronic low back pain[5]

How Pamidronate Works

Pamidronate works in several ways to help improve bone health and manage certain conditions:

  • Slowing Bone Breakdown: It helps to slow down the process of bone breakdown (resorption) in the body[3]
  • Increasing Bone Density: By reducing bone breakdown, it can help increase overall bone density[9]
  • Reducing Pain: In conditions like bone metastases, it can help reduce bone pain[7]
  • Preventing Skeletal-Related Events: In cancer patients, it can help prevent complications like fractures or spinal cord compression[7]

How Pamidronate is Administered

Pamidronate is typically administered intravenously (through a vein). The dosage and frequency can vary depending on the condition being treated:

  • For multiple myeloma or bone metastases, it’s often given every 3-4 weeks[7]
  • For other conditions, it may be given less frequently, such as every few months[1]
  • The infusion usually takes about 2-4 hours[6]

Current Research Areas

Researchers are currently exploring new uses for pamidronate and ways to optimize its use:

  • Chronic Low Back Pain: Studies are investigating if pamidronate can help manage chronic low back pain[5]
  • Combination Therapies: Research is being done on combining pamidronate with other drugs like arsenic trioxide for treating certain cancers[4]
  • Optimizing Treatment Schedules: Studies are looking at different dosing schedules to find the most effective way to administer the drug[7]
  • Local Application: Some research is exploring the local application of pamidronate during hip replacement surgery to prevent bone loss around the implant[9]

Potential Side Effects

Like all medications, pamidronate can cause side effects. Some potential side effects include:

  • Flu-like symptoms (fever, chills, body aches)
  • Nausea or vomiting
  • Fatigue
  • Low blood calcium levels
  • Kidney problems (in rare cases)
  • Osteonecrosis of the jaw (a rare but serious condition affecting the jawbone)

It’s important to discuss potential side effects with your healthcare provider before starting treatment with pamidronate[3].

Condition Study Type Dosage Primary Outcome
Avascular necrosis of femoral head Prospective study 0.5mg/kg initial, 1mg/kg subsequent Prevention of femoral head collapse
SAPHO syndrome Unrandomized, open-label 1 mg/kg, IV, for 3 days every 3 months Change in MRI results
Bone loss after liver transplant Randomized, double-blind 90 mg at 7-12 days and 3 months post-transplant Change in bone mineral density
Advanced solid tumors or multiple myeloma Phase I trial Dose escalation study Maximum tolerated dose
Chronic low back pain Randomized, double-blind 30mg, 60mg, 90mg, or 180mg Change in pain severity
Breast cancer with bone metastases Randomized, multicenter 90 mg IV every 3-4 weeks Time to first skeletal event

FAQ

  • What is Pamidronate Disodium? Pamidronate Disodium is a bisphosphonate medication that helps prevent bone loss and strengthen bones. It is being studied in clinical trials for various conditions, including bone disorders, cancer-related bone complications, and other medical issues.
  • What conditions are being studied with Pamidronate Disodium? Clinical trials are exploring the use of Pamidronate Disodium in conditions such as avascular necrosis of the femoral head, SAPHO syndrome, bone loss associated with liver transplant, multiple myeloma, chronic low back pain, and breast cancer with bone metastases.
  • How is Pamidronate Disodium administered in these trials? In most trials, Pamidronate Disodium is administered intravenously (IV). The dosage and frequency of administration vary depending on the specific study and condition being treated.
  • What are the potential benefits of Pamidronate Disodium? Potential benefits being studied include prevention of bone loss, reduction in skeletal-related events, pain relief, and improved bone mineral density. However, the exact benefits may vary depending on the specific condition and study design.
  • Are there any side effects associated with Pamidronate Disodium? While side effects can vary, common ones may include flu-like symptoms, bone pain, and changes in blood calcium levels. The clinical trials are also assessing the safety profile of Pamidronate Disodium in different patient populations.

Ongoing Clinical Trials on Pamidronate Disodium

  • Study of Pamidronate for Pain Relief in Patients with Sternocostoclavicular Hyperostosis (SCCH)

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing Setrusumab and Bisphosphonates for Children with Osteogenesis Imperfecta

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland

  • Study on Treating Osteogenesis Imperfecta in Patients Using Teriparatide and Zoledronic Acid

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Ireland The Netherlands

Glossary

  • Avascular necrosis: A condition where bone tissue dies due to lack of blood supply, often affecting the hip joint.
  • SAPHO syndrome: A rare condition characterized by synovitis, acne, pustulosis, hyperostosis, and osteitis.
  • Bisphosphonate: A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
  • Bone mineral density (BMD): A measurement of the amount of calcium and other minerals in a segment of bone, used to diagnose osteoporosis.
  • Skeletal-related event (SRE): Complications of bone metastases, including fractures, spinal cord compression, or need for radiation or surgery to bone.
  • Multiple myeloma: A cancer of plasma cells, a type of white blood cell, that can cause bone damage.
  • Osteocalcin: A protein found in bone and dentin, used as a biochemical marker for bone formation.
  • Pamidronate Disodium: A bisphosphonate medication used to treat high blood calcium levels, osteoporosis, and bone pain from some types of cancer.

References

  1. https://clinicaltrials.gov/study/NCT02007915
  2. https://clinicaltrials.gov/study/NCT02544659
  3. https://clinicaltrials.gov/study/NCT00657852
  4. https://clinicaltrials.gov/study/NCT00124605
  5. https://clinicaltrials.gov/study/NCT01210599
  6. https://clinicaltrials.gov/study/NCT00033332
  7. https://clinicaltrials.gov/study/NCT00128297
  8. https://clinicaltrials.gov/study/NCT00738257
  9. https://clinicaltrials.gov/study/NCT00548288